Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesPretreatment prognostic factors influencing distant metastasis-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy
American Journal of Clinical Oncology, 10/06/09
Jerimic B et al. – This analysis showed that only stage grouping and concurrent CHT predicted DMFS in patients with locally advanced squamous cell carcinoma of the head and neck treated with RT with and without concurrent low-dose daily CHT. These results may have implication for future studies in this disease.
Methods- 2 consecutive prospective randomized trials
- 289 patients treated with standard fraction (conventionally fractionated [CF]) or hyperfractionated radiation therapy with or without concurrent low-dose daily platinum chemotherapy (CHT)
- Kaplan-Meier analysis showed that gender and age did not influence DMFS
- T stage , and primary tumor location . N stage , stage grouping , treatment , and concurrent CHT influenced DMFS
- Univariate Cox analysis showed treatment lost significance, whereas N staging became marginally insignificant
- Multivariate Cox analysis showed that only lower stage grouping and addition of concurrent CHT were independent prognosticator of improved DMFS
Today in Radiotherapy (XRT)...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2×2 randomised clinical trial in patients with low risk of recurrence
European Journal of Cancer, 11/05/09
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/11/09
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Sponsor
Article Search
Sponsor